Finance

Lists
Why is HROW down 3,80%?
Dive Deeper
HROW:NASDAQ
Harrow Inc
29,36 $
-3,80%
(-1,16) 1D
29,61 $
+0,85% (+0,25)
After hours
Closed: 9 հոկ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HROW...
Open
30,73 $
High
30,90 $
Low
27,00 $
Mkt. cap
1,10 մլրդ
Avg. vol.
550,16 հզր
Volume
1,35 մլն
52-wk high
54,85 $
52-wk low
27,00 $
EPS
-1,00 $
Beta
0,19
Shares outstanding
37,49 մլն
No. of employees
373
Open
30,73 $
High
30,90 $
Low
27,00 $
Mkt. cap
1,10 մլրդ
Avg. vol.
550,16 հզր
Volume
1,35 մլն
52-wk high
54,85 $
52-wk low
27,00 $
EPS
-1,00 $
Beta
0,19
Shares outstanding
37,49 մլն
No. of employees
373
News stories
From web sources and news partners
Profile
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee. Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing. In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary. Wikipedia
About Harrow Inc
CEOMark L. Baum Esq.
Employees373
Founded2012
HeadquartersՆեշվիլ, Թենեսի, Միացյալ Նահանգներ
Sector-
Websiteharrow.com
Analyst ratings
Based on 8 analysts giving stock ratings to HROW in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for HROW in the last 3 months.
Highest
Current 29,36 $
88,00 $ (+199,73%)
Average
64,33 $ (+119,11%)
Lowest
45,00 $ (+53,27%)
Analyst
Recommendation
Action
Price target
Projected
Date
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
10/05/2026
Thomas Flaten
Lake Street
Buy
Maintained
60,00 $
+104,4%
10/05/2026
Chase Knickerbocker
Craig-Hallum
Buy
Maintained
-
-
09/29/2026
Daniel Clark
Leerink Partners
Buy
Initiated
45,00 $
+53,3%
09/09/2026
Thomas Shrader
BTIG
Buy
Maintained
63,00 $
+114,6%
08/25/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
70,00 $
+138,4%
08/12/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
88,00 $
+199,7%
08/10/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
60,00 $
+104,4%
08/10/2026
Jeffrey Cohen
Ladenburg Thalmann & Co.
Buy
Reiterated
62,00 $
+111,2%
03/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
71,64 մլն
89,09 մլն
44,20 մլն
70,66 մլն
Cost of goods sold
17,71 մլն
18,47 մլն
17,16 մլն
20,30 մլն
Cost of revenue
17,71 մլն
18,47 մլն
17,16 մլն
20,30 մլն
Research and development expenses
3,32 մլն
11,72 մլն
5,90 մլն
8,07 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
35,86 մլն
43,31 մլն
43,23 մլն
53,30 մլն
Operating expense
39,18 մլն
55,03 մլն
49,12 մլն
61,37 մլն
Total operating expenses
56,89 մլն
73,50 մլն
66,28 մլն
81,67 մլն
Operating income
14,75 մլն
15,59 մլն
-22,08 մլն
-11,01 մլն
Other non operating income
61,00 հզր
-8,00 հզր
-
-
EBT including unusual items
1,02 մլն
10,40 մլն
-27,58 մլն
-17,27 մլն
EBT excluding unusual items
8,77 մլն
10,40 մլն
-27,58 մլն
-17,27 մլն
Income tax expense
-
3,77 մլն
25,00 հզր
-
Effective tax rate
-
36,27%
-0,09%
-
Other operating expenses
-
-
-
-
Net income
1,02 մլն
6,63 մլն
-27,60 մլն
-17,27 մլն
Net profit margin
1,42%
7,44%
-62,44%
-24,44%
Earnings per share
0,33
0,27
-0,74
-0,46
Interest and investment income
-
-
-
-
Interest expense
-6,04 մլն
-5,19 մլն
-5,50 մլն
-6,26 մլն
Net interest expenses
-6,04 մլն
-5,19 մլն
-5,50 մլն
-6,26 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
19,31 մլն
20,22 մլն
-16,50 մլն
-5,02 մլն
Gain or loss from assets sale
-
13,00 հզր
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google Apps